Pyxis Oncology posts corporate deck outlining strategy to build differentiated antibody-drug conjugate company around MICVO program in head and neck cancer

Pyxis Oncology, Inc.

Pyxis Oncology, Inc.

PYXS

0.00
  • Pyxis Oncology highlighted MICVO, an extracellular-targeting antibody-drug conjugate in clinical development that targets EDB+FN in tumor extracellular matrix.
  • Phase 1 dose escalation dosed 80 patients across 18 sites, exploring 0.3-8.0 mg/kg Q3W, with dose-dependent responses starting at 3.6 mg/kg.
  • In R/M HNSCC, responses were reported at 3.6 mg/kg and 5.4 mg/kg; confirmed ORR was 50% with 100% disease control rate.
  • 5.4 mg/kg was selected for dose expansion based on benefit-risk; monotherapy received FDA Fast Track designation.
  • Multiple clinical data catalysts were flagged for 2H 2026, including monotherapy dose expansion in 2L+ R/M HNSCC and MICVO with KEYTRUDA dose escalation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.